1. Home
  2. ANAB vs XHR Comparison

ANAB vs XHR Comparison

Compare ANAB & XHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AnaptysBio Inc.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$48.44

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Xenia Hotels & Resorts Inc.

XHR

Xenia Hotels & Resorts Inc.

HOLD

Current Price

$19.49

Market Cap

1.6B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
XHR
Founded
2005
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
ANAB
XHR
Price
$48.44
$19.49
Analyst Decision
Strong Buy
Buy
Analyst Count
8
6
Target Price
★ $87.25
$21.10
AVG Volume (30 Days)
510.1K
★ 773.6K
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
★ 2.87%
EPS Growth
91.02
★ 326.67
EPS
N/A
★ N/A
Revenue
$234,603,000.00
★ $1,078,500,000.00
Revenue This Year
$17.97
$4.53
Revenue Next Year
$36.88
$2.60
P/E Ratio
★ N/A
$95.81
Revenue Growth
★ 157.01
3.80
52 Week Low
$30.27
$11.75
52 Week High
$73.30
$22.06

Technical Indicators

Market Signals
Indicator
ANAB
XHR
Relative Strength Index (RSI) 48.05 69.01
Support Level $44.43 $18.57
Resistance Level $51.27 $19.82
Average True Range (ATR) 2.29 0.45
MACD 0.44 0.17
Stochastic Oscillator 58.84 80.47

Price Performance

Historical Comparison
ANAB
XHR

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About XHR Xenia Hotels & Resorts Inc.

Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other regions. Xenia's revenue is divided between the sale of rooms, food and beverages, and other sources.

Share on Social Networks: